While short sellers exercise ever more influence on Canadian public companies, the regulatory regime governing these speculators has remained somewhat static. As we’ve seen in the recent case of Valeant Pharmaceuticals International, a company’s reputation can be formidably challenged and further scrutiny invited following the actions of a single player.
Companies responding to a short seller’s report can face significant downward pressure on the market price of their securities.
PAUL SIMON – Globe and Mail – March 30, 2016.
Want More Investigative Content?
